Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by APXiMAB™, the Company's proprietary antibody drug discovery platform. Its lead immuno-oncology drug candidate, APX005M, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.